Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 53.28% is 199% above its 5-year average of -53.56%, near the high end of its 5-year range (-100.42%–53.28%).
206.17% above its 12-month average of -50.19%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -0.32%.
RETURN ON ASSETS (ROA)
53.28%
RETURN ON ASSETS (ROA) AVG TTM
-50.19%
RETURN ON ASSETS (ROA) AVG 3Y
-57.97%
RETURN ON ASSETS (ROA) AVG 5Y
-53.56%
RETURN ON ASSETS (ROA) AVG 10Y
-64.74%
RETURN ON ASSETS (ROA) AVG 15Y
-67.28%
RETURN ON ASSETS (ROA) AVG 20Y
-74.36%
CURRENT VS TTM AVG
+206.17%
CURRENT VS 3Y AVG
+191.91%
CURRENT VS 5Y AVG
+199.48%
CURRENT VS 10Y AVG
+182.30%
CURRENT VS 15Y AVG
+179.19%
CURRENT VS 20Y AVG
+171.65%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+265.26%
vs the sector median at left
Agenus Inc.
Market Cap
$318.77M
Return on Assets (ROA)
53.28%
TTM Avg
-50.19%
3Y Avg
-57.97%
5Y Avg
-53.56%
Market Cap
$319.56M
Return on Assets (ROA)
-90.17%
TTM Avg
-81.88%
3Y Avg
-55.65%
5Y Avg
-44.24%
Market Cap
$321.44M
Return on Assets (ROA)
-46.30%
TTM Avg
-31.23%
3Y Avg
-20.32%
5Y Avg
-24.57%
Market Cap
$322.03M
Return on Assets (ROA)
-70.63%
TTM Avg
-82.15%
3Y Avg
-59.06%
5Y Avg
-50.33%
Market Cap
$324.34M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
Market Cap
$326.76M
Return on Assets (ROA)
-160.64%
TTM Avg
-128.90%
3Y Avg
-103.44%
5Y Avg
-103.44%
Market Cap
$312.71M
Return on Assets (ROA)
-28.22%
TTM Avg
-29.68%
3Y Avg
-31.08%
5Y Avg
-26.24%
Market Cap
$301.07M
Return on Assets (ROA)
-96.57%
TTM Avg
-96.57%
3Y Avg
-96.57%
5Y Avg
-96.57%
Market Cap
$301.29M
Return on Assets (ROA)
-24.94%
TTM Avg
-31.51%
3Y Avg
-135.72%
5Y Avg
-152.11%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agenus Inc. (AGEN) | $318.77M | 53.28% | -50.19% | -57.97% | -53.56% |
| Avita Medical Inc. (RCEL)vs › | $319.56M | -90.17% | -81.88% | -55.65% | -44.24% |
| Sanara MedTech Inc. (SMTI)vs › | $321.44M | -46.30% | -31.23% | -20.32% | -24.57% |
| Cabaletta Bio, Inc. (CABA)vs › | $322.03M | -70.63% | -82.15% | -59.06% | -50.33% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $324.34M | -39.85% | -37.20% | -38.95% | -33.46% |
| CapsoVision, Inc. (CV)vs › | $326.76M | -160.64% | -128.90% | -103.44% | -103.44% |
| C4 Therapeutics, Inc. (CCCC)vs › | $312.71M | -28.22% | -29.68% | -31.08% | -26.24% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $301.07M | -96.57% | -96.57% | -96.57% | -96.57% |
| Benitec Biopharma Inc. (BNTC)vs › | $301.29M | -24.94% | -31.51% | -135.72% | -152.11% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.84M | -104.42% | -76.93% | -55.08% | -54.19% |
ROA
53.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 0.05% |
| 2024-12-31 | -100.42% |
| 2023-12-31 | -78.29% |
| 2022-12-31 | -53.22% |
| 2021-12-31 | -5.13% |
| 2020-12-31 | -84.34% |
| 2019-12-31 | -69.31% |
| 2018-12-31 | -117.08% |
| 2017-12-31 | -87.20% |
| 2016-12-31 | -80.90% |
| 2015-12-31 | -36.28% |
| 2014-12-31 | -57.01% |
| 2013-12-31 | -86.33% |
| 2012-12-31 | -32.66% |
| 2011-12-31 | -117.51% |
| 2010-12-31 | -70.88% |
| 2009-12-31 | -66.09% |
| 2008-12-31 | -50.40% |
| 2007-12-31 | -82.62% |
| 2006-12-31 | -71.12% |
| 2005-12-31 | -71.15% |
| 2004-12-31 | -42.21% |
| 2003-12-31 | -47.07% |
| 2002-12-31 | -62.74% |
| 2001-12-31 | -78.61% |
| 2000-12-31 | -36.52% |
| 1999-12-31 | -32.32% |
